2023 Update on Hepatitis C Virus (HCV) and Fatty Liver Disease

1. Metabolic Syndrome, including insulin resistance, dyslipidemia and hypertension, are correlated with NASH.

a) True
b) False

2. The Non-Alcoholic Fatty Liver Disease (NAFLD) spectrum starts are early diagnosis of Non-Alcoholic Steatohepatitis (NASH), progressing into fibrosis and ending with cirrhosis.

a) True
b) False

3. Non-Alcoholic Steatohepatitis (NASH) is the most common indicator for liver transplantation in women in the United States.

a) True
b) False

4. Four stages of fibrosis include(s):

a) Periportal OR perisinusoidal
b) Periportal AND perisinusoidal
c) Bridging Fibrosis
d) Cirrhosis
e) All of the above

5. Metformin is not effective in treating NASH for diabetic nor non-diabetic patients.

a) True
b) False

6. Weight Management interventions used to manage NAFLD include(s):

a) Traditional lifestyle interventions
b) Apps for weight loss support
c) EndoBariatric Procedures
d) Bariatric Surgery (Roux-en-Y gastric bypass/ Gastrectomy sleeve)
e) All of the above

7. Hepatitis C is the #1 blood-borne infection and cause of liver cancer in the United States.

a) True
b) False

8. The medications approved for treatment of Hepatitis C include(s):

a) Epclusa
b) Vosevi
c) Mavyret
d) Zepatier
e) All of the above

9. Hepatitis C has a 95% cure rate after just 12 weeks of treatment.

a) True
b) False